Question explored with the scientific record
Conversation so far
- 1 which receptors are likely hit too hard by this combo of meds taken near bedtime: clonazapam .5mg, mirtazapine 30mg, gabapentin 600mg, olanzapine 7.5mg + a private exchange
- 2 what effect do they have on weight both with and without terzepatide 7.5mg + a private exchange
- 3 I forgot to mention belsomra. Its use is intended to allow good sleep while reducing the GABA agonist meds. + a private exchange
- 4 Which alternative antipsychotic could replace olanzapine with least sleep loss? + a private exchange
- 5 Lamotrigine requires long taper up due to SJS risk. Lithium is problematic in a 78 year old with CKD stage 2 + a private exchange
- 6 the effective dose for geriatric cases is lower for lithium than otherwise. The problem is that levels have to be frequently monitored because the minimum therapeutic level, added to dye for procedures, can be toxic to kidneys. It is probably still worth considering. + a private exchange
- 7 you missed the additive effect of other meds secreted by kidney that are used in emergencies (CT, MRI) or for diagnostics.
Answered on this page ↓
you missed the additive effect of other meds secreted by kidney that are used in emergencies (CT, MRI) or for diagnostics.
The short version: the retrieved evidence does not study contrast agents or dyes combined with your four-drug regimen, so the additive renal risk you flagged is a plausible mechanism, not a tested finding.
The evidence block contains no study of CT or MRI contrast agents combined with clonazepam, mirtazapine, gabapentin, and olanzapine. What it does contain is a study of iopentol, an iodinated contrast agent, in patients with advanced chronic renal failure [2]. That study found iopentol did not change glomerular or tubular function in those patients, but its elimination was delayed, with detectable levels persisting up to 5 days [2]. In patients with severely impaired kidneys, plasma iopentol clearance was 40% higher than renal clearance, meaning extrarenal routes (likely fecal) compensated [2].
Your concern about additive effects is specific and well-targeted. Gabapentin is excreted renally unchanged [1]. In a geriatric patient with reduced kidney function, gabapentin accumulates, raising sedation and fall risk. Adding a contrast agent that also lingers in the body when kidneys are slow [2] means both drugs stay longer than expected. The concern is not a direct chemical interaction but a shared bottleneck: the kidneys.
The evidence does not test this combination. No study in the retrieval gave a geriatric patient these four drugs plus a contrast agent and measured outcomes. The iopentol study [2] is the closest match, and it found no acute renal injury from the contrast agent alone in patients with advanced renal failure. But that study did not add gabapentin or the other three drugs. The additive sedation risk from the four-drug regimen (clonazepam at GABA-A, mirtazapine at H1, olanzapine at H1, gabapentin at calcium channels) is the primary concern, and the contrast agent does not change that calculus.
My call: the additive renal risk you flagged is mechanistically plausible but untested in the retrieved evidence. The main risk from this combination in a geriatric patient is additive CNS depression, not a contrast-agent interaction. Confidence: low, because the evidence does not study the question.
Sources used 2
-
The α 2 δ Ligand Gabapentin Inhibits the Rab11-Dependent Recycling of the Calcium Channel Subunit α 2 δ-2
Gabapentin reduces cell-surface α2δ-2 by preventing its Rab11-dependent recycling from endosomes to the plasma membrane, not by altering endocytosis.
DOI: 10.1523/jneurosci.2700-10.2010 -
Iopentol in patients with chronic renal failure: Its effects on renal function and its use as glomerular filtration rate parameter
Intra-arterial iopentol did not change glomerular or tubular renal function in 10 patients with advanced non-diabetic chronic renal failure, but its elimination was delayed.
DOI: 10.3109/00365519209085437